Gas-Fragmentation Study of the Novel Synthetic Zwitterionic Drug 3-Methyl-9-(2-oxa-2 Lambda 5-2H-1,3,2-oxazaphosphorine-2-cyclohexyl)-3,6,9-triazaspiro[5,5]undecane Chloride (Slxm-2) by Electrospray Ionization Tandem Mass Spectrometry

Siting Wang,Yan Song,Jiao Wang,Xiaomei Ling,Zemei Ge,Runtao Li,Jingrong Cui
DOI: https://doi.org/10.1002/rcm.4501
2010-01-01
Abstract:The zwitterionic drug 3-methyl-9-(2-oxa-2lambda5-2H-1,3,2-oxazaphosphorine-2-cyclohexyl)-3,6,9-triazaspiro[5,5]undecane chloride (SLXM-2) is a novel synthetic compound which has shown anticancer activity and low toxicity in vivo. In this study, the various gas-phase fragmentation routes were analyzed by electrospray ionization mass spectrometry (positive ion mode) in conjunction with tandem mass spectrometry (ESI-MS(n)) for the first time. In ESI-MS the fragment ion at m/z 289 (base peak) was formed by loss of the chlorine anion from the zwitterionic precursor SLXM-2. The fragment ion at m/z 232 was formed from the ion at m/z 289 by loss of 1-methylaziridine. The detailed gas-phase collision-induced dissociation (CID) fragmentation mechanisms obtained from the various precursor ions extracted from the zwitterionic SLXM-2 drug was obtained by tandem mass spectrometry analyses.
What problem does this paper attempt to address?